Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 6, Issue 5, Pages 721-733Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECI.10.49
Keywords
ankylosing spondylitis; anti-INF agent; golimumab; monoclonal antibody; psoriatic arthritis; rheumatoid arthritis
Categories
Ask authors/readers for more resources
Rheumatoid arthritis (RA) is a chronic inflammatory systemic disease characterized by symmetric arthritis leading to progressive erosion of cartilage and bone. Psoriatic arthritis and ankylosing spondylitis are also inflammatory arthritides that belong to the spondyloarthritides. Disease-modifying anti-rheumatic drugs and biologic therapies including anti-TNF agents are used in their treatment. The TNF antagonists have shown rapid and sustained therapeutic responses. However, a substantial number of patients fail to respond to anti-TNF agents or experience side effects. Golimumab is a human monoclonal antibody to TNF-alpha requiring less frequent administration compared with current anti-TNF products. Various trials have shown promising results in terms of efficacy and safety in methotrexate-naive and -resistant patients with RA as well as in patients previously treated with other anti-TNF agents. The efficacy of golimumab has also been demonstrated in patients with psoriatic arthritis and ankylosing spondylitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available